Dr. Alberts Discusses Updates in Liver Cancer | OncLive

Dr. Alberts Discusses Updates in Liver Cancer

September 26, 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).

At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.


x